Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease

Authors

• Joshua T. Dearborn, Washington University School of Medicine in St. Louis
• Keigo Takahashi, Washington University School of Medicine in St. Louis
• Nicholas R. Rensing, Washington University School of Medicine in St. Louis
• Michael Wong, Washington University School of Medicine in St. Louis
• Jonathan D. Cooper, Washington University School of Medicine in St. Louis
• Mark S. Sands, Washington University School of Medicine in St. Louis

Journal

PLoS One

Publication Date

1-1-2026

Volume

21

Issue

7

First Page

e0337880

Document Type

Open Access Publication

DOI

10.1371/journal.pone.0337880

Rights and Permissions

Dearborn JT, Takahashi K, Rensing NR, Wong M, Cooper JD, Sands MS. Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease. PLoS One. 2026 Jul 20;21(7):e0337880. doi: 10.1371/journal.pone.0337880. © 2026 Dearborn et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Dearborn, Joshua T.; Takahashi, Keigo; Rensing, Nicholas R.; Wong, Michael; Cooper, Jonathan D.; and Sands, Mark S., "Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease." PLoS One. 21, 7. e0337880 (2026).
https://digitalcommons.wustl.edu/oa_4/7541

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.